Merck’s stock demonstrated modest movement on the XETRA exchange, trading at €141.70, with intraday fluctuations between €142.15 and €140.35. Despite reporting impressive quarterly sales growth of 3.46 percent to €5.35 billion, the stock continues to trade significantly below its 52-week high of €177.00 recorded on August 30, 2024. The pharmaceutical giant’s market capitalization stands at €18.3 billion, though the share price has experienced a monthly decline of 7.46 percent. Recent trading activity shows minimal momentum, with a slight uptick of 0.11 percent to €141.95 at the start of December 2024.
Analyst Outlook and Dividends
The company’s financial prospects remain promising, with analysts maintaining optimistic projections. The average price target is set at €186.71, with thirteen analysts issuing buy recommendations. The DZ BANK recently adjusted their fair value assessment slightly downward to €201 from €205 while maintaining a positive recommendation. Shareholders can anticipate increased returns, as the dividend is expected to rise from €2.20 in 2023 to €2.35 in the current year, with projected earnings of €8.78 per share for 2024.
Ad
Merck Stock: New Analysis – 03 December
Fresh Merck information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.
Read our updated Merck analysis…
Merck’s stock demonstrated modest movement on the XETRA exchange, trading at €141.70, with intraday fluctuations between €142.15 and €140.35. Despite reporting impressive quarterly sales growth of 3.46 percent to €5.35 billion, the stock continues to trade significantly below its 52-week high of €177.00 recorded on August 30, 2024. The pharmaceutical giant’s market capitalization stands at €18.3 billion, though the share price has experienced a monthly decline of 7.46 percent. Recent trading activity shows minimal momentum, with a slight uptick of 0.11 percent to €141.95 at the start of December 2024.
Analyst Outlook and Dividends
The company’s financial prospects remain promising, with analysts maintaining optimistic projections. The average price target is set at €186.71, with thirteen analysts issuing buy recommendations. The DZ BANK recently adjusted their fair value assessment slightly downward to €201 from €205 while maintaining a positive recommendation. Shareholders can anticipate increased returns, as the dividend is expected to rise from €2.20 in 2023 to €2.35 in the current year, with projected earnings of €8.78 per share for 2024.
Ad
Fresh Merck information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.